Binding EC50 of all three bsTCEs to human monocytes was equal, whereas binding EC50 of the Vγ9 bsTCEs to human Vγ9Vδ2-T cells was ∼30- to 60-fold higher compared with CD1d-Vδ2 bsTCE; however, this did not affect degranulation EC50 and tumor lysis (Figures 7A and S6C–S6E). The gene discussed is CD1D; the disease is neoplasm.